S. Faderl

1.6k total citations
24 papers, 1.2k citations indexed

About

S. Faderl is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, S. Faderl has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 10 papers in Genetics and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in S. Faderl's work include Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). S. Faderl is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). S. Faderl collaborates with scholars based in United States, Malaysia and United Kingdom. S. Faderl's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Guillermo Garcia‐Manero, Elihu H. Estey, William G. Wierda, Gautam Borthakur, Srđan Verstovšek, Sherry Pierce and J. Shan and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Haematology.

In The Last Decade

S. Faderl

24 papers receiving 1.2k citations

Peers

Countries citing papers authored by S. Faderl

Since Specialization

Citations

This map shows the geographic impact of S. Faderl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Faderl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Faderl more than expected).

Fields of papers citing papers by S. Faderl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Faderl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Faderl. The network helps show where S. Faderl may publish in the future.

Co-authorship network of co-authors of S. Faderl

This figure shows the co-authorship network connecting the top 25 collaborators of S. Faderl. A scholar is included among the top collaborators of S. Faderl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Faderl. S. Faderl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome 2015 ·Leukemia ·Francesco Paolo Tambaro, Guillermo Garcia‐Manero, Susan O’Brien, S. Faderl, Alessandra Ferrajoli, JA Burger, Sherry Pierce, X Wang, K-A Do, Hagop M. Kantarjian, M Keating, William G. Wierda	10
2	Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion 2014 ·Haematologica ·Paolo Strati, Michael J. Keating, Susan O’Brien, Alessandra Ferrajoli, Jan A. Burger, S. Faderl, Francesco Paolo Tambaro, Nitin Jain, William G. Wierda	45
3	Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson 2013 ·Leukemia ·Megan Othus, Hagop M. Kantarjian, Stephen H. Petersdorf, Farhad Ravandi, John E. Godwin, Jörge E. Cortes, Sherry Pierce, Harry P. Erba, S. Faderl, F R Appelbaum, Elihu H. Estey	117
4	Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Elias Jabbour, Hady Ghanem, Xuelin Huang, Farhad Ravandi, Guillermo Garcia‐Manero, Susan O’Brien, S. Faderl, Sherry Pierce, Sangbum Choi, Srđan Verstovšek, Mark Brandt, Jörge E. Cortes, Hagop M. Kantarjian	12
5	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies 2012 ·Haematologica ·Gautam Borthakur, Michael G. Rosenblum, Moshe Talpaz, (unknown), Farhad Ravandi, S. Faderl, Emil J. Freireich, Tapan M. Kadia, G. García-Manero, Hagop M. Kantarjian, Jörge E. Cortes	60
6	Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia 2012 ·Haematologica ·Aziz Nazha, Jörge E. Cortes, S. Faderl, Sherry Pierce, (unknown), (unknown), G. Borthakur, Rajyalakshmi Luthra, Hagop Kantarjian, (unknown)	40
7	Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation 2012 ·Leukemia ·Ye Chen, Hagop M. Kantarjian, Sherry Pierce, S. Faderl, Susan O’Brien, Wei Qiao, Lynne V. Abruzzo, Marcos de Lima, Partow Kebriaei, Elias Jabbour, Naval Daver, Tapan M. Kadia, Zeev Estrov, Guillermo Garcia‐Manero, Jörge E. Cortes, Farhad Ravandi	41
8	Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia 2011 ·British Journal of Haematology ·Pamela S. Becker, Hagop M. Kantarjian, Frederick R. Appelbaum, Stephen H. Petersdorf, Barry E. Storer, Sherry Pierce, Jianqin Shan, Paul C. Hendrie, John M. Pagel, Andrei R. Shustov, Derek L. Stirewalt, S. Faderl, Elizabeth B. Harrington, Elihu H. Estey	64
9	Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients 2011 ·Haematologica ·(unknown), Sergej Konoplev, E. Lin, (unknown), S. Faderl, (unknown), (unknown), Mark Brandt, Jörge E. Cortes, H. Kantarjian, (unknown)	10
10	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias 2010 ·Haematologica ·G. Borthakur, Hagop M. Kantarjian, Farhad Ravandi, Wendong Zhang, Marina Konopleva, James R. Wright, S. Faderl, Srđan Verstovšek, (unknown), M. Andreeff, Jörge E. Cortes	159
11	Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). 2010 ·Journal of Clinical Oncology ·(unknown), Susan O’Brien, S. Faderl, F. Ravandi Kashani, William G. Wierda, M. Andreeff, Rebecca Garris, Richard Champlin, Jörge E. Cortes, H. Kantarjian	28
12	Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL). 2010 ·Journal of Clinical Oncology ·(unknown), H. Kantarjian, (unknown), Susan O’Brien, F. Ravandi Kashani, Charles Koller, Jan A. Burger, Rebecca Garris, (unknown), S. Faderl	1
13	Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome 2009 ·Bone Marrow Transplantation ·(unknown), Marcos de Lima, Hagop M. Kantarjian, S. Faderl, Partow Kebriaei, Sergio Giralt, Jan Davisson, Guillermo Garcia‐Manero, Richard E. Champlin, Jean‐Pierre J. Issa, Farhad Ravandi	64
14	Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome 2009 ·Leukemia ·Ravindra Kumar Garg, S. Faderl, G. García-Manero, Jörge E. Cortes, Charles Koller, (unknown), (unknown), Sherry Pierce, Mark Brandt, Miloslav Beran, Gautam Borthakur, Hagop M. Kantarjian, Farhad Ravandi	40
15	A prognostic score for patients with lower risk myelodysplastic syndrome 2007 ·Leukemia ·Guillermo Garcia‐Manero, J. Shan, S. Faderl, Jörge E. Cortes, Farhad Ravandi, Gautam Borthakur, William G. Wierda, Sherry Pierce, Elihu H. Estey, (unknown), Xuelin Huang, Hagop M. Kantarjian	222
16	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes 2005 ·Leukemia Research ·Francis J. Giles, Hagop M. Kantarjian, Jörge E. Cortes, S. Faderl, Srđan Verstovšek, Deborah A. Thomas, Guillermo Garcia‐Manero, William G. Wierda, Alessandra Ferrajoli, Stephen Kornblau, Gloria Mattiuzzi, Apostolia M. Tsimberidou, Maher Albitar, Susan O’Brien, Elihu H. Estey	10
17	Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia 2003 ·Leukemia Research ·Apostolia M. Tsimberidou, Jörge E. Cortes, Deborah A. Thomas, Guillermo Garcia‐Manero, Srđan Verstovšek, S. Faderl, Maher Albitar, Hagop M. Kantarjian, Elihu H. Estey, Francis J. Giles	59
18	Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia 2003 ·Cancer Chemotherapy and Pharmacology ·Yesid Alvarado, Jörge E. Cortes, Srđan Verstovšek, Deborah A. Thomas, S. Faderl, Zeev Estrov, Hagop M. Kantarjian, (unknown)	29
19	Bone marrow cyclooxygenase‐2 levels are elevated in chronic‐phase chronic myeloid leukaemia and are associated with reduced survival 2002 ·British Journal of Haematology ·Francis J. Giles, Hagop M. Kantarjian, B. Nebiyou Bekele, Jörge E. Cortes, S. Faderl, Deborah A. Thomas, Taghi Manshouri, Anna Rogers, Michael J. Keating, Moshe Talpaz, Susan O’Brien, Maher Albitar	34
20	Clinical significance of minimal residual disease in leukemia. 2000 ·International Journal of Oncology ·S. Faderl, Hagop M. Kantarjian, Moshe Talpaz, Zeev Estrov	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact